TCF3 and neoplasm: In summary, our findings show that the combined application of GSK126 and 5-Aza synergistically inhibited EZH2 and DNMT3B to derepress the expression of TCF3, and profoundly blocked EC tumor progression in mouse models (Fig. 6K).